Targeting Wnts at the Source—New Mechanisms, New Biomarkers, New Drugs
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Wnt signaling is dysregulated in many cancers and is therefore an attractive therapeutic target. The focus of drug development has recently shifted away from downstream inhibitors of β-catenin. Active inhibitors of Wnt secretion and Wnt/receptor interactions have been developed that are now entering clinical trials. Such agents include inhibitors of Wnt secretion, as well as recombinant proteins that minimize Wnt–Frizzled interactions. These new therapies arrive together with the recent insight that cancer-specific upregulation of Wnt receptors at the cell surface regulates cellular sensitivity to Wnts. Loss-of-function mutations in RNF43 or ZNRF3 and gain-of-function chromosome translocations involving RSPO2 and RSPO3 are surprisingly common and markedly increase Wnt/β-catenin signaling in response to secreted Wnts. These mutations may be predictive biomarkers to select patients responsive to newly developed upstream Wnt inhibitors. Mol Cancer Ther; 14(5); 1087–94. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
(2012) · doi:10.1016/j.jmoldx.2011.08.002 · Cited by 2,567 · cited 1×
“With the development of sensitive monoclonal antibodies and recent advances in techniques such as RNAscope (68) that allow for reliable quantification of gene expression on formalin-fixed tissues, profiling of expression of these genes might be useful for patient selection.”
MethodRomosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Wang, K., Yuen, S. T., Xu, J., Lee, S. P., Yan, H. H. N., Shi, S. T., Siu, H. C., Deng, S., Chu, K. M., Law, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2983 · Cited by 1,045
Recurrent R-spondin fusions in colon cancer
Seshagiri, S., Stawiski, E. W., Durinck, S., Modrusan, Z., Storm, E. E., Conboy, C. B., Chaudhuri, S., Guan, Y., Janakiraman, V., Jaiswal, B. S., et al. (2012) · Nature · doi:10.1038/nature11282 · Cited by 960
The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength
de Lau, W., Peng, W. C., Gros, P., & Clevers, H. (2014) · Genes & Development · doi:10.1101/gad.235473.113 · Cited by 656
Secreted and transmembrane wnt inhibitors and activators
Cruciat, C.-M., & Niehrs, C. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a015081 · Cited by 646
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 2×
“The tumors with elevated expression of RSPO either due to translocations or due to amplifications could also potentially respond to PORCN inhibitors, anti-Fzd antibodies, or antiRSPO antibodies (19, 25).”
Background
Cited by
Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer
Snaebjornsson, M. T., Janaki-Raman, S., & Schulze, A. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.010 · Cited by 1,097
Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer
Wang, Y., Zheng, L., Shang, W., Yang, Z., Li, T., Liu, F., Shao, W., Lv, L., Chai, L., Qu, L., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01008-w · Cited by 422
WNT signalling in prostate cancer
Murillo-Garzón, V., & Kypta, R. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.144 · Cited by 361
Wnt addiction of genetically defined cancers reversed by PORCN inhibition
Madan, B., Ke, Z., Harmston, N., Ho, S. Y., Frois, A. O., Alam, J., Jeyaraj, D. A., Pendharkar, V, Ghosh, K., Virshup, I. H., et al. (2016) · Oncogene · doi:10.1038/onc.2015.280 · Cited by 341
Self-citationSteinhart, Z., Pavlovic, Z., Chandrashekhar, M., Hart, T., Wang, X., Zhang, X., Robitaille, M., Brown, K. R., Jaksani, S., Overmeer, R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4219 · Cited by 297
Metadata
- Authors
- Madan, B., & Virshup, D. M.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2015-05-01
- Volume
- 14
- Issue
- 5
- Pages
- 1087-1094
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2073027692
- Cited by
- 114
- References
- 14
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Wnts at the Source—New Mechanisms, New Biomarkers, New Drugs. https://app.cochat.ai/papers/10.1158/1535-7163.mct-14-1038
- The paper
- Madan, B., & Virshup, D. M. (2015). Targeting Wnts at the Source—New Mechanisms, New Biomarkers, New Drugs. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-1038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.